<?xml version="1.0" encoding="UTF-8"?>
<p>Ethically the rigor of and scientifically valid clinical trials must be continued during epidemics. Active stakeholder engagement may reduce this risk, as illustrated with HIV,
 <fn id="dewb12283-note-1009">
  <label>9</label>
  <p>West Slevin, K., Ukpong, M., &amp; Heise, L. (2008). Community Engagement in HIV Prevention Trials: Evolution of the Field and Opportunities for Growth. Aids2031 Science and Technology Working Group, No 11; Philpott. S., Heise, L., McGrory, E., et al. The challenge of defining standards of prevention in HIV prevention trials. J Med Ethics 
   <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/jme.2010.037176" xmlns:xlink="http://www.w3.org/1999/xlink">https://doi.org/10.1136/jme.2010.037176</ext-link>.
  </p>
 </fn> malaria, tuberculosis, genetics and genomics, mental health, biobanks and nanotechnology research.
 <fn id="dewb12283-note-1010">
  <label>10</label>
  <p>Gesell, S.B., Klein, K.P., Halladay, J., et al. (2017). Methods guiding stakeholder engagement in planning a pragmatic study on changing stroke systems of care. J Clin Transl Sci. 1(2), 121‐128.</p>
 </fn> Critical factors stemming from stakeholder engagement include prompt translation of research findings into policies and programs, and the fostering of collaborative partnership and social value of the study for the participant communities.
 <fn id="dewb12283-note-1011">
  <label>11</label>
  <p>Reynolds, L., &amp; Sariola, S. (2018). The ethics and politics of community engagement in global health research. Critical Public Health. 28(3), 2570268.</p>
 </fn>
</p>
